2017
DOI: 10.4172/2155-9929.1000342
|View full text |Cite
|
Sign up to set email alerts
|

Comparative Immunohistochemical Study of P63, SMA, CD10 and Calponin in Distinguishing In Situ from Invasive Breast Carcinoma

Abstract: Background: Loss of the outer myoepithelial layer is the hallmark of invasive carcinoma, and demonstration of this loss can be documented by immunohistochemical techniques. The purpose of this study was to compare the specificity and sensitivity of four of the most commonly used-markers of myoepithelial cells: P63, SMA, CD10 and Calponin in distinguishing in situ from invasive breast carcinoma.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

2
1
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 10 publications
2
1
0
Order By: Relevance
“…No significant difference in staining was noted between highgrade and low-grade DCIS. This was similar to studies done by Khazai et al [4] and Abdallah et al [7]. The discontinuous staining in these cases may be due to ductal expansion associated with DCIS, resulting in fading of the myoepithelial cells.…”
Section: Discussionsupporting
confidence: 91%
See 1 more Smart Citation
“…No significant difference in staining was noted between highgrade and low-grade DCIS. This was similar to studies done by Khazai et al [4] and Abdallah et al [7]. The discontinuous staining in these cases may be due to ductal expansion associated with DCIS, resulting in fading of the myoepithelial cells.…”
Section: Discussionsupporting
confidence: 91%
“…Different cytokeratins are described in the luminal and basal cell types, whereas myoepithelial cells express basal cell-type cytokeratins, smooth muscle actin, calponin, and p63. An intact myoepithelial layer is often seen in benign and in situ lesions, whereas loss of this layer is considered a diagnostic feature of invasive cancer [4][5][6][7]. p63 is a specific nuclear marker for myoepithelial cells of the breast with no known cross-reactivity and, therefore, may aid in differentiating benign lesions from malignant lesions [8].…”
Section: Introductionmentioning
confidence: 99%
“…Abdallah et al . recently reported computational measurements of the sensitivity of calponin, P63, CD10, and αSMA in demonstrating the myoepithelium of DCIS lesions, with results comparable to our “naïve method” [18]. …”
Section: Resultssupporting
confidence: 56%